Zhengye Biotechnology Holding Ltd (ZYBT) stock
ZYBTNasdaqPharmaceutical Preparations
$1.50−0.02 (-1.32%)
Close on Nov 18, 2026Market cap $71.09MP/E –Yield –
Zhengye Biotechnology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -CN¥70.51M, down 528.9% from the year before.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -CN¥70.51M | -528.9% |
| FY2024 | Dec 31, 2024 | CN¥16.44M | -63.5% |
| FY2023 | Dec 31, 2023 | CN¥44.99M | -31.7% |
| FY2022 | Dec 31, 2022 | CN¥65.83M | – |
See a number that looks wrong?